학술논문

Obesity and Fat Metabolism in Human Immunodeficiency Virus–Infected Individuals: Immunopathogenic Mechanisms and Clinical Implications
Document Type
article
Source
The Journal of Infectious Diseases. 220(3)
Subject
Medical Microbiology
Biomedical and Clinical Sciences
Immunology
Diabetes
Sexually Transmitted Infections
Prevention
HIV/AIDS
Nutrition
Infectious Diseases
Clinical Research
Obesity
Aetiology
2.1 Biological and endogenous factors
Infection
Metabolic and endocrine
Oral and gastrointestinal
Adipocytes
Adipogenesis
Adipose Tissue
Adolescent
Adult
Cytokines
Fats
Female
HIV
HIV Infections
Humans
Inflammation
Insulin Resistance
Lipid Metabolism
Male
Middle Aged
Viral Proteins
Young Adult
obesity
viral proteins
inflammation
metabolism
Biological Sciences
Medical and Health Sciences
Microbiology
Biological sciences
Biomedical and clinical sciences
Health sciences
Language
Abstract
Metabolic complications relating to complex effects of viral and immune-mediated mechanisms are now a focus of clinical care among persons living with human immunodeficiency virus (PLHIV), and obesity is emerging as a critical problem. To address knowledge gaps, the US National Institutes of Health sponsored a symposium in May 2018 entitled "Obesity and Fat Metabolism in HIV-infected Individuals." Mechanisms relating to adipose dysfunction and fibrosis, immune function, inflammation, and gastrointestinal integrity were highlighted as contributors to obesity among PLHIV. Fibrotic subcutaneous adipose tissue is metabolically dysfunctional and loses its capacity to expand, leading to fat redistribution, including visceral obesity and ectopic fat accumulation, promoting insulin resistance. Viral proteins, including viral protein R and negative regulatory factor, have effects on adipogenic pathways and cellular metabolism in resident macrophages and T cells. HIV also affects immune cell trafficking into the adipose compartments, with effects on adipogenesis, lipolysis, and ectopic fat accumulation. Key cellular metabolic functions are likely to be affected in PLHIV by gut-derived cytokines and altered microbiota. There are limited strategies to reduce obesity specifically in PLHIV. Enhancing our understanding of critical pathogenic mechanisms will enable the development of novel therapeutics that may normalize adipose tissue function and distribution, reduce inflammation, and improve insulin sensitivity in PLHIV.